P3 Health Partners Inc. (NASDAQ:PIII – Get Free Report) shares were up 8.9% during trading on Monday . The stock traded as high as $10.91 and last traded at $10.48. 34,665 shares changed hands during trading, an increase of 36% from the average session volume of 25,404 shares. The stock had previously closed at $9.62.
Analyst Ratings Changes
Several research firms have recently weighed in on PIII. UBS Group set a $14.00 price target on P3 Health Partners in a research note on Friday, May 15th. TD Cowen reaffirmed a “hold” rating and set a $14.00 price objective (up from $3.00) on shares of P3 Health Partners in a research report on Friday, May 22nd. Weiss Ratings upgraded P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. Lake Street Capital reiterated a “buy” rating and issued a $14.00 price objective (up from $4.00) on shares of P3 Health Partners in a report on Friday, May 15th. Finally, Wall Street Zen raised P3 Health Partners to a “hold” rating in a research report on Saturday, July 4th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, P3 Health Partners presently has an average rating of “Hold” and a consensus target price of $14.00.
Get Our Latest Research Report on P3 Health Partners
P3 Health Partners Price Performance
P3 Health Partners (NASDAQ:PIII – Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.85) by $5.17. The company had revenue of $386.39 million during the quarter, compared to analysts’ expectations of $391.45 million.
Hedge Funds Weigh In On P3 Health Partners
A hedge fund recently bought a new position in P3 Health Partners stock. Lido Advisors LLC acquired a new position in P3 Health Partners Inc. (NASDAQ:PIII – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,748 shares of the company’s stock, valued at approximately $33,000. Lido Advisors LLC owned 0.15% of P3 Health Partners at the end of the most recent reporting period. 7.75% of the stock is currently owned by institutional investors.
P3 Health Partners Company Profile
P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.
The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.
Further Reading
- Five stocks we like better than P3 Health Partners
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for P3 Health Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for P3 Health Partners and related companies with MarketBeat.com's FREE daily email newsletter.
